Auxilium Buys Actient As Base Business Weakens
This article was originally published in The Pink Sheet Daily
Executive Summary
The acquisition will establish Auxilium as a leading urology company and add nine commercial products. But the $585 million upfront acquisition price is expensive for Auxilium, as sales of its own products slump.
You may also be interested in...
Start-Up Quarterly Statistics, Q2 2013
The year might have started off slow for start-up fundraising ($398.7 million in Q1), but during the second quarter of 2013 life science companies rallied and earned a whopping $907.2 million. There were several reverse licensing arrangements as well as alliances involving large molecule-focused start-ups.
Xiaflex Sales Still Slow, But Other Indications In The Works
Auxilium’s Xiaflex sales still languish, but its older testosterone product continues to drive growth for the company.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.